Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1990 1
1994 1
1997 1
1998 1
2000 3
2001 6
2002 5
2003 4
2004 6
2005 6
2006 11
2007 9
2008 6
2009 7
2010 6
2011 11
2012 10
2013 7
2014 13
2015 8
2016 3
2017 3
2018 5
2019 8
2020 2
2021 0
Text availability
Article attribute
Article type
Publication date

Search Results

133 results
Results by year
Filters applied: . Clear all
Page 1
Immunogenicity and safety of the combined vaccine for measles, mumps, and rubella isolated or combined with the varicella component administered at 3-month intervals: randomised study.
Santos EMD, Noronha TG, Alves IS, Cruz RLS, Ferroco CLV, Brum RC, Oliveira PMN, Siqueira MM, Lima MC, Ramos FLP, Bragagnolo CM, Camacho LAB, Maia MLS. Santos EMD, et al. Mem Inst Oswaldo Cruz. 2019 Mar 7;114:e180517. doi: 10.1590/0074-02760180517. Mem Inst Oswaldo Cruz. 2019. PMID: 30843921 Free PMC article. Clinical Trial.
Immunogenicity and safety of a novel MMR vaccine (live, freeze-dried) containing the Edmonston-Zagreb measles strain, the Hoshino mumps strain, and the RA 27/3 rubella strain: Results of a randomized, comparative, active controlled phase III clinical trial.
Sood A, Mitra M, Joshi HA, Nayak US, Siddaiah P, Babu TR, Mahapatro S, Sanmukhani J, Gupta G, Mittal R, Glueck R. Sood A, et al. Hum Vaccin Immunother. 2017 Jul 3;13(7):1523-1530. doi: 10.1080/21645515.2017.1302629. Epub 2017 Mar 31. Hum Vaccin Immunother. 2017. PMID: 28362563 Free PMC article. Clinical Trial.
Immunogenicity and Safety of a Measles-Mumps-Rubella Vaccine Administered as a First Dose to Children Aged 12 to 15 Months: A Phase III, Randomized, Noninferiority, Lot-to-Lot Consistency Study.
Klein NP, Abu-Elyazeed R, Povey M, Macias Parra M, Diez-Domingo J, Ahonen A, Korhonen T, Tinoco JC, Weiner L, Marshall GS, Silas PE, Sarpong KO, Ramsey KP, Fling JA, Speicher D, Campos M, Munjal I, Peltier C, Vesikari T, Baccarini C, Caplanusi A, Gillard P, Carryn S, Henry O. Klein NP, et al. J Pediatric Infect Dis Soc. 2020 Apr 30;9(2):194-201. doi: 10.1093/jpids/piz010. J Pediatric Infect Dis Soc. 2020. PMID: 30849175 Free PMC article. Clinical Trial.
Immunogenicity and safety of measles-rubella vaccine co-administered with attenuated Japanese encephalitis SA 14-14-2 vaccine in infants aged 8 months in China: a non-inferiority randomised controlled trial.
Li Y, Chu SY, Yue C, Wannemuehler K, Xie S, Zhang F, Wang Y, Zhang Y, Ma R, Li Y, Zuo Z, Rodewald L, Xiao Q, Feng Z, Wang H, An Z. Li Y, et al. Lancet Infect Dis. 2019 Apr;19(4):402-409. doi: 10.1016/S1473-3099(18)30650-9. Epub 2019 Mar 1. Lancet Infect Dis. 2019. PMID: 30833160 Clinical Trial.
Immunogenicity and safety of measles-mumps-rubella vaccine delivered by disposable-syringe jet injector in India: A randomized, parallel group, non-inferiority trial.
Bavdekar A, Oswal J, Ramanan PV, Aundhkar C, Venugopal P, Kapse D, Miller T, McGray S, Zehrung D, Kulkarni PS; SII MMR author group. Bavdekar A, et al. Vaccine. 2018 Feb 21;36(9):1220-1226. doi: 10.1016/j.vaccine.2018.01.006. Epub 2018 Feb 1. Vaccine. 2018. PMID: 29395526 Free PMC article. Clinical Trial.
A second dose of a measles-mumps-rubella vaccine administered to healthy four-to-six-year-old children: a phase III, observer-blind, randomized, safety and immunogenicity study comparing GSK MMR and MMR II with and without DTaP-IPV and varicella vaccines co-administration.
MMR-158 Study Group. MMR-158 Study Group. Hum Vaccin Immunother. 2019;15(4):786-799. doi: 10.1080/21645515.2018.1554971. Epub 2019 Feb 20. Hum Vaccin Immunother. 2019. PMID: 30785357 Free PMC article. Clinical Trial.
133 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page